|
|
 |
Systemic Anti-infective
|
 |
Anti-fungal agent
|
 |
Vaginal, esophageal, urinary, systemic, Yeast Infection, cryptococcal meningitis.
|
 |
Doses are tablet, suspension, or IV. (Adults) Adjust according to patient response. Vaginal Yeast Infection: Single 150 mg tablet. Other Yeast Infections: 200mg on 1st day, followed by 100 mg once daily. Continue treatment for >2 weeks. Esophageal Yeast Infection 200 mg on 1st day, followed by 100mg once daily for minimum of 3 weeks. Systemic Yeast Infection: Optimal dosage not established; max. 400 mg/day. UYI, peritonitis: 50 to 200 mg/day. Cryptococcal meningitis: 400 mg on 1st day, followed by 200 to 400 mg once daily. Duration of treatment is 10 to 12 weeks before or after meal.
|
 |
Category C
|
 |
Nausea, headache, skin rash, vomiting, abdominal pain, diarrhea. More frequent in AIDS.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
